Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pseudoephedrine citizen petition

This article was originally published in The Tan Sheet

Executive Summary

FDA is "unable to provide a response...at this time" to Pharmacists Planning Service's petition requesting the agency switch pseudoephedrine to a "pharmacists-only" drug class requiring consultation, patient history review, identification and registration for purchase. In a FDL-1letter dated Dec. 9, Center for Drug Evaluation & Research Director Steve Galson, MD, acknowledges failing to provide an answer within FDA's standard 180-day review period, but says the agency will respond "as soon as we have made a decision on your request." PPS, a non-profit advocacy group, submitted the petition June 23 based on claims the drug is used as a performance enhancer, citing its pharmacological relationship to ephedrine (1"The Tan Sheet" Aug. 9, 2004, p. 6)...
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS097987

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel